# Effectiveness of a New Anti-HIV Drug (AG1549) Plus Viracept (Nelfinavir) Plus Combivir (Zidovudine/Lamivudine) in HIV-Infected Patients

> **NCT00004999** · PHASE2 · SUSPENDED · sponsor: **Agouron Pharmaceuticals** · enrollment: 350 (—)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Lamivudine/Zidovudine
- **DRUG:** Capravirine
- **DRUG:** Nelfinavir mesylate

## Key facts

- **NCT ID:** NCT00004999
- **Lead sponsor:** Agouron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 1999-08
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 350 (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00004999

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00004999, "Effectiveness of a New Anti-HIV Drug (AG1549) Plus Viracept (Nelfinavir) Plus Combivir (Zidovudine/Lamivudine) in HIV-Infected Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00004999. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*